Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab IP Infusion in Advanced Gastric Cancer with Peritoneal Metastasis
NCT04222114Phase 3Unknown
- Sponsor
- LintonPharm Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of catumaxomab in gastric cancer (GC) (2 arms), sponsored by LintonPharm Co., Ltd. Primary endpoint: Overall Survival at 1 year. Status: unknown.
02
Drugs
catumaxomab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04222114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222114.